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A Novel Eukaryote-Like CRISPR Activation Tool in Bacteria:
Features and Capabilities
Yang Liu and Baojun Wang*
CRISPR (clustered regularly interspaced short palindromic repeats) activation
(CRISPRa) in bacteria is an attractive method for programmable gene
activation. Recently, a eukaryote-like, 𝝈54-dependent CRISPRa system has
been reported. It exhibits high dynamic ranges and permits flexible target site
selection. Here, an overview of the existing strategies of CRISPRa in bacteria
is presented, and the characteristics and design principles of the CRISPRa
system are introduced. Possible scenarios for applying the eukaryote-like
CRISPRa system is discussed with corresponding suggestions for
performance optimization and future functional expansion. The authors
envision the new eukaryote-like CRISPRa system enabling novel designs in
multiplexed gene regulation and promoting research in the 𝝈54-dependent
gene regulatory networks among a variety of biotechnology relevant or
disease-associated bacterial species.
1. Introduction
CRISPR (clustered regularly interspaced short palindromic re-
peats) activation (CRISPRa) is a power and versatile technology
for genetic engineering and biological research. The innate pro-
grammability from the CRISPR module offers unprecedented
flexibility to turn on any target gene of interest. Its programmabil-
ity was instrumental to CRISPR, which is an adaptive immunity
in bacteria.[1–3] Prokaryotes have evolved mechanisms to protect
themselves against exogenous DNA/RNA. They were performed
by endonucleases that recognize the invasive species through
RNA/DNA or RNA/RNA complementary pairing and then cleav-
ing them.[4,5] By exploiting the sequence-specific “identification
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friend or foe” system, scientists are
able to guide the endonucleases to
their desired DNA or RNA targets.[5–8]
CRISPR regulation relies on inactivated
CRISPR endonucleases. The nuclease-
deficient CRISPR DNA endonucleases,
for instances dCas9 and ddCpf1 (dCas12),
are effectively programmable DNA bind-
ing domains. When these domains are
tethered to transactivation domains or
subunits of RNA polymerase, they ac-
tivate the promoters near the CRISPR
target sites. This strategy has been
widely utilized in both eukaryotes and
prokaryotes,[9–17] particularly in the former,
where the transcription activation mecha-
nisms and the activators are well-studied.
While CRISPRa in eukaryotes enjoys
much success and is continuously im-
proved, the development of CRISPRa in
prokaryotes had stagnated.[10,15,16] Bikard et al. reported the
first bacterial CRISPRa device to employ an RNA polymerase
𝜔-subunit fused dCas9 in a 𝜔-deleted strain.[10] The second
CRISPRa device has an E. coli activator SoxS, which was recruited
to the dCas9 through the engineered single guide RNA (sgRNA)
and an RNA-binding domain fused to the activator. SoxS inter-
acts with the 𝛼-subunit of RNA polymerase. This enhances the
activation efficacy and removes the prerequisite on host strain
genetic backgrounds.[15] Recently, a dCas9-fused anti-sigma fac-
tor AsiA was employed for a CRISPRa system, which enriched
the bacterial CRISPRa toolbox.[17]
The above introduced bacterial CRISPRa systems are designed
for bacterial 𝜎70-dependent genes, which perform most house-
keeping functions.[18] CRISPRa systems for many other genes
were still unavailable, for instance, many other biological func-
tions that respond to environmental changes under the control
of the 𝜎54 factor, the only sigma factor apart from 𝜎70 responsible
for regulating various functions.[19] The 𝜎54-dependent promot-
ers have a distinct activationmechanism from its 𝜎70 counterpart,
with a unique promoter structure and its own set of conserved
core sequences.[20] Their regulations work over long distances
with a DNA looping structure, similar to that of the RNA poly-
merase II in eukaryotes. Hence, 𝜎54 activation is also known as
eukaryote-like gene activation in bacteria.[21–25] Much of the regu-
latory networks and biological functions of 𝜎54-dependent genes
remain elusive, a situation that hindered the standardization and
application of 𝜎54-dependent promoters in genetic engineering.
Recently, we developed a CRISPRa system for 𝜎54-dependent
genes. It supports high dynamic range regulation with low
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Table 1. Comparison between existing bacterial CRISPRa systems.
Cas protein Regulator Activator attachment mode Target promoters Host cell background requirement
CRISPR/dCas9 𝜔-subunit Protein fusion/gRNA scaffold mediated 𝜎70 promoter E. coli ΔrpoZ[10]
CRISPR/dCas9 SoxS gRNA scaffold mediated 𝜎70/38/32/24 promoter None in E. coli[15]
CRISPR/dCas9 AsiA (including mutant) Protein fusion/gRNA scaffold mediated 𝜎70 promoter None in E. coli, K. oxytoca, S. enterica (for
protein fusion) & 𝜎70 F563Y mutated E.




gRNA scaffold mediated 𝜎54 promoter None in E. coli, K. oxytoca, E. coli ΔpspF (for
enhanced function),[16]
CRISPR/dCas9 𝜎 factors Protein fusion 𝜎70 promoter None inM. xanthus[26]
CRISPR/dCas9 TetD gRNA scaffold mediated 𝜎70 promoter None in E. coli[15]
CRISPR/dCas9 - DNA looping 𝜎70/54 promoter None in E. coli[27]
expression leakiness.[16] Thanks to the flexible DNA looping
and the inherently long-distance regulation, CRISPRa target
sites can be placed over a wider physical range. Furthermore,
it enables direct activation of many 𝜎54-dependent promoters,
which otherwise have to be activated by environmental stim-
uli that would have global effects and complicate experimen-
tal control. These properties of our CRISPRa, together with our
discoveries of CRISPRa design principles, will facilitate the re-
search in 𝜎54-dependent gene regulatory networks and the ap-
plications of 𝜎54-dependent promoters in synthetic biology and
industry.
We illustrated the application of the 𝜎54-dependent CRISPRa
by two examples. We built a two-layered cascaded activation and
a positive feedback regulation. These circuits demonstrated the
potential of our CRIPSRa to build complex gene regulatory net-
works. We also used a standardized 𝜎54 promoter library to im-
plement a high throughput method for screening the multi-gene
expression profile. A multi-gRNA generator circuit was designed
to optimize amulti-gene pathway by projecting various transcrip-
tion profiles onto it. We envision that the success of our CRISPRa
design and its application would open up exciting opportuni-
ties, and encourage other scientists to apply the eukaryote-like
CRISPRa system for their scientific endeavors.
2. Existing CRISPR Activation Methods in Bacteria
To date, three canonical CRISPRa systems and one gene acti-
vation device using CRISPR-mediated DNA looping have been
proven in bacteria. Here we briefly summarize their designs,
properties, and their suitable applications (Table 1). The sum-
mary, therefore, is an abridged development history of bacte-
rial CRISPRa. By compare and contrast, we would highlight the
unique features and capabilities of our eukaryote-like CRISPRa
system.
2.1. The 𝝎-Subunit Based CRISPR Activation
Fundamentally, all CRISPRa systems capitalize on the natural
modularity of genetic regulators or RNA polymerases, where
separable domains are independently responsible for DNA bind-
ing, regulation, and recruitment of RNA polymerase or other
transcription factors. These domains can be mixed and matched,
and would trigger transcription activation as long as they are
fused or assembled together to bring the RNApolymerase and ac-
cessory transcription factors to the vicinity of the promoter. This
simple and yet robust characteristic is also the cornerstone of the
two-hybrid system, which screens for molecular interactions in
vivo: Candidate proteins/domains are fused to a DNA binding
domain and an activation domain respectively. Any interaction
between candidates would recruit the activation domain to the
DNA binding domain and activate the promoter nearby, which
converts interaction into observable gene expression.
The sufficiency of an activator-RNA polymerase interaction
to initiate bacterial transcription was first reported in 1997. It
was simultaneously the first reported bacterial two-hybrid (B2H)
system that utilized the 𝛼-subunit of the RNA polymerase.[28,29]
This was followed by Dove and Hochschild in 1998, who showed
that the 𝜔-subunit of the RNA holoenzyme could also be used
to recruit and stabilize the RNA polymerase to enhance tran-
scription initiation.[30] This system, however, only works when
the endogenous copy of the 𝜔-subunit (rpoZ) has been knocked
out.
The 𝜔-subunit is an important component in RNA holoen-
zyme, which can respond to the alarmone ppGpp during strin-
gent response and broadly regulate gene transcription. However,
the 𝜔-subunit (rpoZ) is not essential and its knockout does not
significantly affect the E. coli host growth rate. Hence the func-
tion of this subunit was once vague and controversial for a long
time.[31–33] The interaction between the 𝜔-subunit and the other
subunits of RNA polymerase is thought to contribute to its ability
of transcription initiation.
Building on this information, Bikard et al. reported the first
bacterial CRISPRa by fusing the 𝜔-subunit to the dCas9.[10] The
gRNA then brings the fused protein upstream of a constitutive
promoter for activation (Figure 1a). Fusion can take place on
the N or C terminal of dCas9. Since the 𝜔-subunit is fused di-
rectly to dCas9, there is no additional design requirements to
retrofit the gRNA structure. Activation at the optimal target site
yielded a 23-fold dynamic range. The system works best on weak
promoters—increasing the strength of the constitutive promoter
decreases observable fold change in activation. Intuitively, strong
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Figure 1. Design of bacterial CRISPR gene activation systems. a) The bacterial CRISPRa is designed based on the interaction between the CRISPR/dCas9
complex and the core unit of RNA polymerase.[10,15] b) The bacterial CRISPRa is designed to depend on the interaction between the CRISPR/dCas9
complex and the 𝜎 factors.[15,17,26] c) The eukaryote-like CRISPRa for 𝜎54-dependent promoters, which rely on the ATP-dependent “unlocking” function
by the 𝜎54-dependent activators.[16] d) The bacterial CRISPRa based on programmable DNA looping by an engineered dCas9 dimer.[27] e) The TetD-
mediated CRISPRa, which has an unknown interaction mechanism between the activator and the RNA holoenzyme.[15]
constitutive promoters by definition already have high affinities
with the RNA polymerase and additional recruitment through
the 𝜔-subunit would be insignificant.
Bikard’s CRISPRa system is highly sensitive to the distance
between the CRISPR target site and the transcription start site
(TSS), and they demonstrated a functional range of 20 bp. How-
ever, subsequent research using the phage-assisted continuous
evolution (PACE) to evolve protospacer adjacent motif (PAM)
compatibility-broad dxCas9 appeared to suggest a periodic varia-
tion of the activation efficiency along with the variation of the dis-
tance between TSS and the target site.[34] Such periodic variation
of the activation efficiency that accompanies target site shift was
also observed in both other bacterial CRISPRa systems, a feature
that is likely a result of the molecular spatial orientation change
owing to the periodic DNA helix structure. In another CRISPRa
study, the RNApolymerase𝜔-subunit was fused to theMCPRNA
adaptor, which can be recruited to target promoters using an en-
gineered sgRNA scaffold with an MS2 RNA aptamer (Figure 1a).
However, this design resulted in weak CRISPRa activation.[15]
2.2. The CRISPR Activation Based on the AraC/XylS Family
Activators and Sigma Factors
The second CRISPRa system differs from the work by Bikard et
al. in the activator, and the strategy in which the activator was
linked to the dCas9/gRNA complex.[15] Dong et al. adopted the
design fromCRISPRawork in eukaryotic cells. TheRNAaptamer
MS2 is incorporated into the sgRNA scaffold, which recruits an
RNA binding adaptor MCP domain fused to the activator (Fig-
ure 1a). This design has two advantages: 1) Recruitment of the ac-
tivator through gRNA instead of direct fusion to dCas9 avoids un-
predictable steric and functional interference to either of the two
domains. 2) Different sgRNA on different target sites/promoters
can now mediate CRISPRa or CRISPRi independently, depend-
ing on whether an activator is recruited to the sgRNA.[12]
To obtain a potent activation domain, the authors then
screened several candidate bacteria activators, hijackers and RNA
polymerase subunits, and identified the AraC/XylS family ac-
tivators SoxS and TetD. SoxS yields the strongest activation
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efficiency and its CRISPRa system is functional in wild type E.
coli, eliminating the need for gene knockouts in host strains.
The two AraC/XylS family activators SoxS and TetD have differ-
ent activation mechanisms.[35] Previous researches revealed that
SoxS interacts with the 𝛼-subunit to activate transcription, while
the interaction mechanism of TetD and RNA polymerase is still
unclear[35–37] (Figure 1a,e). This suggested that this CRISPRa sys-
tem may, in general, operate through the 𝛼-subunit. Yet surpris-
ingly, using the 𝛼-subunit directly as the activator would not give
significant CRISPRa activity, and the underlying reason is un-
clear. However, Peng et al. also reported that the dCas9 fused
with an 𝛼-subunit has weak CRISPRa function in Myxococcus
xanthus.[26] Therefore, 𝛼-subunit mediated CRISPRa might still
be an option but further studies are needed.
In addition, Dong et al. discovered the T4 phage anti-sigma
factor AsiA could act as an activator for CRISPRa when used in a
strain expressing the F563Y 𝜎70 mutant. AsiA normally inhibits
transcription in E. coli by interacting with the 𝜎70 factor.[38–40] This
toxicity could be rescued by the 𝜎70 mutant, which leaves the AsiA
as merely a 𝜎70-binding protein.[41] The CRISPR complex thus
ultimately recruits the 𝜎70 factor to boost transcription. Interest-
ingly, in another recent design, the AsiA was fused directly to the
dCas9, and toxicity was not observed, obviating the need of the
F563Y 𝜎70 mutant. When expressed as part of a fused protein,
AsiA appeared tomaintain its affinity with, but no longer inhibits
the 𝜎70 factor. The fact that direct fusions work for AsiA but not
SoxS suggests that different activators require distinct engineer-
ing strategies depending on their mode of actions.[17]
In use of 𝜎 factors as activators, work by Peng et al. also
reported functional but weak CRISPRa in Myxococcus xanthus
could be obtained by fusing 𝜎70, 𝜎54, or the extracytoplasmic func-
tion (ECF) 𝜎 factor CarQ to dCas9[26] (Figure 1b).
Despite the innovation in design and the choice of activator,
this CRISPRa system is similar to the one by Bikard et al., limited
by the basal strength of target promoters. Thismight reflect a fun-
damental limitation in relying on RNA polymerase subunits to
recruit and stabilize the RNA polymerases. Activation efficiency
is also influenced by the sequences between the target site and
the TSS.[42] Still, there might be an improvement in the distance
between the target site and the TSS, since recent research indi-
cates that a wider range can be tolerated. In addition, activation
efficiencies appeared to alternate like sharp peaks as the distance
between the TSS and target site increased.[42] This phenomenon
might be due to the relative orientation of the activation complex
as the binding site spirals along the DNA helix.
2.3. The Eukaryote-Like CRISPR Activation
The 𝜎54-dependent promoters are a common but special group
in bacteria. As the only promoter type that has a wide range of bi-
ological functions apart from the 𝜎70-dependent promoters, 𝜎54-
dependent promoters generally control the genes that respond to
environmental conditions.[19]
In contrast to 𝜎70-dependent promoters, 𝜎54-dependent pro-
moters require activation for transcription initiation. The 𝜎54
factor has special recognition sequence (–12 box and –24 box
for 𝜎54, while -10 box and -35 box for 𝜎70) and a “blocking”
mechanism to inhibit transcription initiation.[43,44] When a 𝜎54
activator complex binds to an upstream activating sequence
(UAS), DNA looping occurs with the help of integration host fac-
tor (IHF) to facilitate its interaction with the 𝜎54 factor.[45] This is
followed by ATP hydrolysis, which provides the energy to switch
off the “blocking” conformation of the 𝜎54 factor to allow RNA
polymerase initiating the transcription. Since theUAS is far away
from the promoter, the regulation happens over long distances,
and together with the iconic DNA looping structure, the activa-
tionmechanism shares similarity with that of the eukaryotic RNA
polymerase II. Hence 𝜎54 activation is known as the eukaryote-
like activation in bacteria.[21–25,46]
The above properties were taken into consideration in the de-
sign of our CRISPRa based on 𝜎54-dependent promoters, and we
also drew insights from a 𝜎54-based B2H system.[47] Since the
𝜎
54 activator functions as a hexamer, it could not be fused to the
dCas9 protein directly and has to be recruited through an engi-
neered gRNA with at least two RNA aptamers.[16] The original
DNA binding domains in the activator hexamer were deleted and
replaced by RNA binding adaptors (Figure 1c). This allows the
engineered activators to be recruited to the CRISPR complex and
at the same time precludes their activation of native target genes
on the genome. By screening several 𝜎54 activators from different
bacterial species, three 𝜎54 activators (PspF, NorR, WtsA) were
identified that could be engineered to be activators specific for
CRISPRa. During this process, we noted that our candidate 𝜎54
activators are highly diverse and showed little modularity in do-
main functional structures. We concluded that the activator for
the phage shock protein operon (pspABCDE) PspF is the most
potent activator.[16,48–50]
The novel use of 𝜎54-dependent promoters for CRISPRa over-
came some issues faced by other bacterial CRISPRa system. This
systemnot onlyworks in the 𝜎54 activator pspF gene knockout and
wild type E. coli, but also in a non-model bacterium Klebsiella oxy-
toca. There is no restriction on the strength of the target promoter,
because all the 𝜎54-dependent promoters are blocked and are ef-
fectively at “OFF” states unless activated. With the long-distance
regulation mechanism, the target site can be placed much far-
ther away from the TSS. Our thorough characterization between
target site-TSS distance and activation efficacy revealed a wave-
form alternation, demonstrating for the first time a clear spatial
relationship at work in CRISPRa.
2.4. CRISPR Activation by DNA Structure Remodeling
The three methods above rely on tethering an activation do-
main to the CRISPR complex. The fourth method deviated from
this norm by omitting the activator domain, and achieve activa-
tion solely by DNA looping. The dCas9 was engineered to form
dimers and two monomers were targeted to a distantly separated
activator binding site and the promoter.[27] Dimerization of the
bound dCas9 thus brings the two elements into proximity and re-
constitutes a local activated promoter (Figure 1d). Theoretically,
this method could activate both 𝜎70 and 𝜎54 promoters possess-
ing available activation mechanisms, and it is not limited by the
genetic background of the host. A recent study indicates that
the E. coli chromosome is well-mixed and uncompartmentalized,
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further supporting the application potential of this strategy.[51]
However, the dynamic range of this strategy is lower than other
reported methods, and would require much optimization if a
further application is desired.
3. Features of Eukaryote-Like CRISPR Activation
The eukaryote-like CRISPRa system has many unique features
because of its 𝜎54-dependent activation mechanism, some of
which have important value for application in synthetic biology
and industrial production. The following section reviews the fea-
tures and the mechanisms behind.
3.1. Low Background Expression and High Dynamic Range
The key principle underlying 𝜎54-dependent CRISPRa is quite
different from others. In 𝜎70-dependent CRISPRa, the target 𝜎70
promoters have their constitutive transcription initiation efficien-
cies. Activation by the CRISPRa system enhances the transcrip-
tion initiation rates by stabilizing and recruiting RNApolymerase
onto promoters. Whereas for 𝜎54 promoters, activation is the re-
lease of a tightly locked promoter activity. This minimizes the
waste of cellular resources when gene expression is unnecessary.
The transcription output of an activated 𝜎54-dependent pro-
moter can be very strong. This property has been harnessed in
synthetic biology for the construction of digital-like genetic logic
gates and analog signal amplifiers, which optimized biosensors
performances with programmed selectivity and sensitivity.[52–56]
Our eukaryote-like CRISPRa also benefited from this feature and
thus has high dynamic ranges in inducible regulation, which fur-
ther enabled applications that were otherwise impossible.[16]
In our CRISPRa system, in the absence of dCas9, sgRNA and
the activator, background output is almost undetectable. It is
only observed when the activator is constitutively expressed and
causes non-specific activation. This may be explained by random
molecular interactions between the RNA polymerase and the en-
gineered activator. Interestingly, some rare 𝜎54-dependent activa-
tors lack the DNA binding domains and hence rely solely on their
own high expression levels to activate target promoters.[57]
3.2. A Wider Region for Target Site Selection
In 𝜎54-dependent promoter activation, there is little limitation on
the distance between theUAS and the core promoter. In one case,
the UAS could be 1 kb away from the TSS.[58] The interaction be-
tween the activator and the RNA polymerase is made possible by
the eukaryote-like DNA looping structure. In our CRISPRa sys-
tem, this flexibility in molecular structure confers flexibility in
choosing a target site. Within the 40 bp region that we tested,
all target sites were functional. All CRISPR-derived systems re-
quire the presence of PAM. PAM, as its name depicts, is a short
sequence right next to the target DNA region and is the first
recognized element in CRISPR surveillance.[3,59] Our CRISPRa
system increases the chance of finding one because a wider se-
quence space could be used. Moreover, the presence of multiple
operable target sites on the same promoter implies that pro-
grammable, multi-input logic gates can be realized by our
CRISPRa system. This property supports higher degrees of free-
dom for PAM site choosing and programmable multi-input
CRISPRa-enabled logic gate design.
4. Design Principles Learned from the
Eukaryote-Like CRISPRa
Below we summarize the design principles learned during the
construction and optimization of our CRISPRa system. This
should aid the future use of our system by others.
4.1. PAM Site Position is Vital for Artificial Target Promoter
Design
Our CRISPRa system shows an alternating change in the activa-
tion efficiency as the target site slides along the DNA strand, at a
rate of one cycle every 10 bp (Figure 2a). This indicates a spatial
relationship between the activator and the RNApolymerase along
the DNA double helix.[16] The CRISPR-activator complex likely
spirals along the DNA helix and result in alternating displace-
ment between the recruited RNA polymerase and the promoter,
and hence the efficiency (Figure 2a). This finding has important
implications in predicting the output of our CRISPRa system.
Recently, similar observations were reported in other CRISPRa
systems, but the pattern was not identical to ours, which may be
explained by differences in mechanisms.[42]
In our study, we opted for distances of −127 and −107 bp and
obtained an orthogonal library of synthetic CRISPR activatable
promoters that performed well. Future users are recommended
to observe these distances for optimal CRISPRa effects on pspA
promoter.
4.2. sgRNA Scaffold Design Affects the Function of
Eukaryote-Like CRISPRa
For CRISPRa devices utilizing the strategy of the gRNA-recruited
activation domain, the structure of the engineered sgRNA could
affect the function of the CRISPRa system. The design of our
eukaryote-like CRISPRa shows both quantity and location pref-
erence of RNA aptamers in the sgRNA scaffold. Notably, some
specific stem-loop structures could not be engineered and com-
bined as RNA aptamers to achieve functional CRISPR activation.
Due to the underlying diversity of different CRISPRa systems, it
is unknown whether this phenomenon is common for all bac-
terial CRISPRa devices. In summary, it suggests that the gRNA
scaffold structure could be an important factor to affect the func-
tion of CRISPRa.
4.3. dCas9 Mutants Enable PAM Preference Expansion
Locating a PAM is a prerequisite for using the CRISPRa system.
This could pose a challenge for endogenous gene activation, since
a functional PAM (NGG for SpdCas9) may not be present on
the wild type promoter sequence. The problem could be solved
by employing some dCas9 variants that target sequences with
non-canonical PAM. In 2018, Hu et al. generated a number of
dxCas9 that recognize different non-canonical PAM.[34] We uti-
lized the variant dxCas9 3.7 to activate the gene for phage shock
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Figure 2. Two notable design principles derived from the eukaryote-like CRISPRa system. a) The hypothesis of CRISPR-activator complex orbiting the
axis of DNA helix when the UAS shifts along the DNA, which may give rise to the periodic variation of activation efficiency of the CRISPRa system. The
line chart schematically shows the change of activation efficiency with shifting the UAS position along the DNA. b) The utilization of non-canonical PAM
recognizing dxCas9 can target more potential PAM sites on wild type promoters, which could be a useful strategy for all types of CRISPRa system. The
red segment represents the canonical PAM (NGG) site at the upstream of the core promoter region, and the orange segments represent the potential
non-canonical PAM sites. Unlike the dCas9, which only recognizes the NGG PAM, dxCas9 targets a wider range of non-canonical PAM.
protein pspA on the E. coli genome[16] (Figure 2b). We noticed
that a similar strategy was subsequently employed on another
𝜎
70-dependent CRISPRa system.[42]
dxCas9 is not the only option. Nishimasu et al. rationally de-
signed the mutant Cas9 SpCas9-NG, which efficiently cleaves
DNA with non-canonical PAM.[60] A nuclease-deficient version
of Cas9-NG would enable non-canonical PAM recognition in our
CRISPRa system. In addition, other natural CRISPR/Cas9 pro-
teins have their PAM preferences as well, which could be utilized
to expand the PAM preferences of CRISPRa systems.[61–63]
4.4. Digital Response by Feedback Regulation
In synthetic biology, the digital response is a property that is
helpful in signal amplification and cascade control,[64–66] and is
frequently achieved by the introduction of a positive feedback
loop that steepens the response curve.[67–71] Construction of such
loops using CRISPRa in bacteria has long been a challenge due
to insufficient dynamic range and limitation of high basal ex-
pression. Since our CRISPRa overcame such issues, we were
able to implement a positive feedback loop to achieve a digital
response.[16] We foresee this strategy to be of interest in future
research.
5. What does Eukaryote-Like CRISPRa Allow Us
to Do?
CRISPRa technologies are well-posed to address two issues: 1)
Regulation of endogenous genes and 2) Construction of synthetic
gene circuits (Figure 3). Below we discuss the areas in which our
eukaryote-like CRISPRa could contribute, the advantages it of-
fers, and the potential limitations it may face.
5.1. Investigation of the “Dark Matter”—𝝈54-Dependent Gene
Regulatory Networks
𝜎
54-dependent promoters generally control genes that respond
to changes in environmental conditions, and apart from the
𝜎
70-dependent promoters, they are the only class of promot-
ers that is not associated with a specific programmed re-
sponse but controls over various biological functions.[19] This
is supported by the genome-wide DNA binding study that
had identified 135 binding sites for 𝜎54 from the E. coli
genome,[72] and an analysis of 186 𝜎54 promoters and puta-
tive 𝜎54 promoters from 47 species.[73] For instances, 𝜎54 pro-
moters are involved in nitrogen assimilation and fixation,[74–76]
pathogenicity,[77–79] host colonization,[80] motility,[78,80,81] biofilm
formation,[80] quorum sensing,[82,83] stress responses,[76] and en-
vironmental bioremediation[84] (Figure 3).
Basic research of 𝜎54-dependent promoters is crucial for dis-
ease control. The Lyme disease affects about 300 000 peo-
ple every year in the USA, and it has been shown that 𝜎54
activation in Borrelia burgdorferi plays a pivotal role in the
infection and transmission process.[78,85] Virulence in many
other pathogenic bacteria such asHelicobacter pylori,Burkholderia
cenocepacia, Erwinia stewartii (a plant pathogen),Vibrio fischeri (an
aquatic pathogen) is also controlled by gene regulatory networks
that are 𝜎54-dependent.[77,80,86,87]
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Figure 3. Two envisioned application scenarios of the eukaryote-like CRISPRa system: 1) building sophisticated synthetic gene circuits (left), and 2)
studying endogenous 𝜎54-dependent genes that are associated with a wide range of biological functions in various bacterial species (right). For synthetic
gene circuits design, the above figure shows a typical potential example of building genetic logic devices by CRISPRa. For endogenous gene regulation
study, one of the expectation is that the CRISPRa could be used for activating a particular set of 𝜎54-dependent genes uncoupled from their native context,
and hence aid disclosing unknown genetic regulatory networks along with a systems biology approach.
Many putative 𝜎54-dependent promoters were identified from
systems biology and bioinformatics studies, but most remained
unverified due to the complex regulatory background and the
lack ofmolecular tools for precise genetic perturbation. There are
two major reasons behind the difficulty to develop those much
needed tools.
First, 𝜎54-dependent promoters have very diverse structures. In
most cases, the only instantly identifiable elements are the core
regions, the –12 box and –24 box, which are highly conserved.
Regions for DNA looping often have different lengths, and the
UAS for different 𝜎54 activators share little homology with one
another.[88]
Second, some 𝜎54-dependent genes require uncommon lab-
oratory conditions to activate. The provision of such conditions
may require substantial investment and commitment, and thus
hinders the research of those genes. For example, the gene clus-
ter for nitrogen fixation inK. oxytoca is 𝜎54-dependent, and would
only turn on under anaerobic conditions.[89,90]
These limitations can be overcome using the 𝜎54-dependent
CRISPRa system. This system can orthogonally activate 𝜎54-
dependent genes, and therefore assist in the research of their
functions. We demonstrated the proof of concept on two key
promoters in the nitrogen fixation pathway in K. oxytoca, and
successfully activate them under an aerobic condition.[16] Fur-
thermore, our CRISPRa system can also verify putative 𝜎54-
dependent promoters by targeting the CRISPRa complex to the
putative UAS.
5.2. Multi-Gene Expression Profile Control
The programmability of CRISPR derived system facilitates mul-
tiplexed gene regulation. Our CRISPRa system is uniquely suit-
able for this task given its high dynamic range, stability, and
durability. One area of our applications is to accelerate the
construction and screening of metabolic pathway expression
profiles. Such processes are often laborious and time-consuming.
Typically, the identification of an optimal expression profile for a
new metabolic pathway requires the construction of a new pro-
file library, and if the library confers cytotoxicity and burden, it
will have to be rebuilt. To address this issue, we designed a li-
brary with multiple gRNA constitutively expressed, and in dif-
ferent profiles, the same set of gRNA with different strengths
of expression are combined combinatorically (Figure 4a). When
projected through our CRISPRa system, the different production
rates of the gRNA set would translate into different expression
levels of the genes in the target pathway that have corresponding
orthogonal 𝜎54-dependent promoters (Figure 4b,c). The intensity
of projection is tuneable and the same gRNA generator library
could be reused in the optimization of a new metabolic pathway.
5.3. Design of Cellular Computing Devices
CRISPRa-mediated multi-layered cellular computing devices
have achieved much success in eukaryotes,[66,91,92] but so far no
such examples have been reported in bacteria. This is likely due to
the low dynamic ranges of bacterial CRISPRa in the past, which
failed to support cascaded regulation. In addition, no more than
one UAS can be functional in one promoter, so signal integration
and hencemulti-input regulation is difficult to achieve. These two
limitations do not concern the eukaryote-like CRISPRa system,
and we reported a CRISPRa-based cascaded circuit that paves the
way for high-level cellular computing.[16]
6. Potential Future Directions for the
Eukaryote-Like CRISPRa System
Our observations on our CRISPRa system led us to propose the
following ideas for further experimentation and functional ex-
pansion of the system.
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Figure 4. The eukaryote-like bacterial CRISPRa enables efficient expression profile screening and optimization of multi-gene pathways. a) A library of
multi-gRNA generators can produce a set of engineered sgRNAs with different expression profiles. The CRISPRa systemwill be able to project the sgRNA-
associated expression profiles onto a target pathway circuit. The boxes with different colors represent different sgRNA genes, corresponding to their
cognate sgRNAs and targeting 𝜎54 promoters. b) The CRISPRa system works as a projector by projecting massive diverse expression profiles carried by
engineered sgRNAs onto the target multi-gene pathway circuits. c) Schematic shows the workflow of screening multi-gene pathway expression profiles
using our CRISPRa system.
6.1. Activator Optimization by Directed Evolution
Directed evolution has been used to generate a dxCas9 variant
and to optimize a bacterial CRISPRa system.[17,34] This strategy is
universal and would be valuable in improving our eukaryote-like
CRISPRa system. The activator and the sgRNA scaffold could be
evolved to yield more potent variants. Selection pressure can be
set up easily by coupling activation efficiencies to cell survivability
through the expression of a selection marker.
6.2. The Necessity of DNA Looping and Availability of Other
CRISPR/Cas Proteins
In 𝜎54-dependent promoters, the DNA segment between the pro-
moter core region and the enhancer forms a loop structure when
the activator interacts with the RNA polymerase. Often, loop
formation is mediated by the IHF DNA bending protein. The
question is whether the loop is the prerequisite or the effect
of the activator-RNA polymerase interaction. If it is the former,
then there exists a possibility to satisfy that spatial requirement
through an artificially designed flexible structure.
In a previous study, IHF-independent activation of 𝜎54-
dependent promoters could be achieved by substituting the
DNA loop fragment with sequences that are inherently more
flexible.[45] This implies that the loop serves to bend the DNA
such that the bound activator and RNA polymerase can come
into proximity, and if the straining DNA is out of the picture, the
affinity between the activator and the RNA polymerase suffices to
drive activator-RNA polymerase interaction. Hence, we hypothe-
size that a long flexible RNA or peptide linker between the activa-
tor and the CRISPR/Cas complex may provide sufficient spatial
degrees of freedom for the activator-RNA polymerase interaction,
and hence bypass the DNA looping requirement. This flexibility
couldmean that the activator anchors on gRNA scaffold can be re-
located to other parts of the gRNA andwould no longer be limited
to the gRNA structure from Streptococcus pyogenes. If that is pos-
sible, the dCas9:gRNA complex in the CRISPRa systemmight be
further substituted by other CRISPR/Cas systems, for instance,
dCas12.
6.3. Potential Eukaryote-Like CRISPRa on 𝝈70-Dependent
Promoters
We envision that the eukaryote-like CRISPRa system may be
modified to activate 𝜎70-dependent promoters. In a special case,
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the NtrC-family regulator PhhR, a homolog of the 𝜎54 acti-
vators, activates a 𝜎70-dependent promoter by long distance
regulation.[93,94] PhhR has been suggested to interact with the
𝛼-subunit through an IHF-dependent DNA looping structure.
This model may provide a basis to engineer a eukaryote-like 𝜎70-
dependent CRISPRa system.
7. Conclusions and Prospects
CRISPR activation in bacteria has seen much development in
the last 7 years. There are two main strategies in creating
a bacterial CRISPRa system. One is designing an engineered
CRISPR/dCas9 complex that interacts with and stabilizes the
RNA polymerase holoenzyme on weak 𝜎70 promoters. The other
is the eukaryote-like CRISPRa, which recruits a 𝜎54 activator to
a 𝜎54-dependent promoter through the CRISPRa complex. These
two strategies concern two different types of promoters and there-
fore are difficult to be cross-applied to promoters of the other
type.
The eukaryote-like CRISPRa system is applicable to activating
endogenous genes and constructing synthetic circuits. The op-
timization strategy for each application will differ according to
their specific goals. For endogenous gene activation, being flex-
ible in choosing the location of a target site and satisfying PAM
requirements are paramount. Using dCas9 variants that target
non-canonical PAM would be helpful. Whereas in the construc-
tion of synthetic circuits, dynamic range is the key to perfor-
mance. Our eukaryote-like CRISPRa is well-suited given its high
dynamic range and low background output. We further worked
out design principles that serve as guidelines in the optimiza-
tion of dynamic ranges. We believe the future in CRISPR-based
circuits is “CRISPR regulation Supremacy,” where CRISPR reg-
ulation can build complex genetic circuits that are unachievable
using non-programmable gene regulatory devices.
Programmable gene activation is a promising, yet highly
competitive and challenging research field. The eukaryote-like
CRISPRa system fills the long-neglected void of programmable
𝜎
54-dependent promoter activation, andwill expedite the research
𝜎
54-dependent gene regulatory networks. On the other hand, our
system is a novel tool for synthetic circuit design and construc-
tion in synthetic biology. Given a strong interest, we believe ex-
isting CRISPRa technologies will be continuously improved, and
more CRISPRa devices and applications will emerge in the near
future.
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